Updated:
Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.: ACAD on Nasdaq; SEC-reported financials and filings, CIK 0001070494.
Overview
Acadia develops its healthcare business around neurological disorders and rare diseases. Its ACAD shares are listed on Nasdaq. Its principal executive office is in San Diego, CA, United States. For the fiscal year ended 2025-12-31, its originally filed 10-K reports revenue of USD 1,071,505,000; net income of USD 391,000,000; operating cash flow of USD 109,836,000. The filing date is 2026-02-26. At that year-end, its balance sheet reports total assets of USD 1,564,195,000 and cash and cash equivalents of USD 177,695,000. For the earlier fiscal year ended 2024-12-31, the originally reported figures include revenue of USD 957,797,000; net income of USD 226,451,000; operating cash flow of USD 157,719,000; year-end total assets of USD 1,187,756,000; year-end cash and cash equivalents of USD 319,589,000.
Company overview
- Legal name
- ACADIA PHARMACEUTICALS INC
- Classification
- Public company
- Industry (SIC)
- 2834 — Pharmaceutical Preparations
- Headquarters
- San Diego, CA, United States
- Incorporated in
- DE
- Fiscal year end
- December 31
- Ticker
- Nasdaq: ACAD
- SEC CIK
- 0001070494
- Website
- www.acadia.com
Financials
Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.
| Fiscal year | Period end | Revenue | Net income | Total assets | Cash and equivalents | Operating cash flow |
|---|---|---|---|---|---|---|
| FY2025USD | $1.1B | $391.0M | $1.6B | $177.7M | $109.8M | |
| FY2024USD | $957.8M | $226.5M | $1.2B | $319.6M | $157.7M | |
| FY2023USD | $726.4M | -$61.3M | $749.0M | $188.7M | $16.7M | |
| FY2022USD | $517.2M | -$216.0M | $587.8M | $114.8M | -$114.0M |
FY2024. Net income: shown as originally filed; later filings report different values for the same periods.
FY2023. Net income: shown as originally filed; later filings report different values for the same periods.
FY2022. Net income: shown as originally filed; later filings report different values for the same periods.
Recent SEC filings
| Form | Filed | Period | Filing |
|---|---|---|---|
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 10-Q | 10-Q | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 10-Q | 10-Q | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| DEF 14A | DEF 14A | ||
| 8-K | 8-K | ||
| 10-K | 10-K | ||
| 8-K | 8-K |
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Research Acadia Pharmaceuticals Inc. in Altss
Track this company’s investors, transactions and relationships in Altss.